Prof. Judith Feucht appointed as W2 Professor for Cellular Immunotherapies in Cancer

👩‍🔬 As iFIT research group leader, Judith has been doing her research within our Cluster of Excellence since 2020, when she came back to Tuebingen from a 5-year postdoc period in the lab of Dr. Michel Sadelain of the renown Memorial Sloan Kettering Cancer Center in New York. Judith has dedicated her scientific career to CAR T Cell Therapy which has achieved remarkable clinical success in certain hematological diseases, resulting in the approval of CAR therapy by the FDA and the EMA. Despite the clinical success, treatment with currently approved CAR designs is curative only in a fraction of patients. Her research group aims at improving and extending cellular therapies by reprogramming immune cells through innovative gene editing and cell engineering strategies.

🏆 Together with her group, she seeks to enhance CAR efficacy by preventing exhaustion, augmenting functional persistence and by enhancing metabolic fitness in order to translate our insights into improved cellular therapies for patients. This work has already been acknowledged several times in the recent past for example with the Curious Mind Award in Life Sciences 2022 or the Friedmund Neumannn Prize in 2021.

👩‍⚕️ As a clinician scientist, she also works as a pediatrician in the Clinic for Pediatrics and Adolescent Medicine at the Universitätsklinikum Tübingen.